GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Raphael Pharmaceutical RAPH · USD

N/A · US listing · 🇺🇸 United States

Compare

1.51

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Raphael Pharmaceutical

From its filings with the US Securities and Exchange Commission

SEC filings

Raphael Pharmaceutical is based in Las Vegas, Nevada and is incorporated in Nevada. Its shares trade on OTC under the ticker RAPH. The SEC classifies its business as medicinal chemicals & botanical products. In the fiscal year to 31 December 2025, it reported a net loss of $1.3m. At that date it held total assets of $53,000 and shareholders' equity of −$1.4m.

Read the filing on SEC.gov ↗

Company facts

Sector
N/A
Industry
N/A
Listed since
23 Aug 2022
Head office
SUITE 105 - 5348 VEGAS DR., LAS VEGAS, NV, 89108
Incorporated in
NV
Classification
Medicinal Chemicals & Botanical Products
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Ajay DhadhaIndependent Chairman of the Board
  • Mr. Shlomi PiloChief Executive Officer, Director, since 2025$240,000
  • Mr. Guy OfirChief Financial Officer, Director, since 2007$144,000
  • Dr. Igal HayonChief Technology Officer, Director, since 2021$350,000
  • Dr. Yehuda EliyaIndependent Director
  • Mr. Zvi LauferIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Raphael Pharmaceutical Inc. focuses on rheumatoid arthritis and Covid-19 product candidates using CBD oil as API.
  • The company is in pre-clinical development stage for its lead product candidate in rheumatoid arthritis treatment.
  • Raphael Pharmaceutical Inc. leverages CBD oil as active pharmaceutical ingredient for both RA and Covid-19 product candidates.

Weaknesses

  • Raphael Pharmaceutical Inc. has limited operation history in the pharmaceutical industry.
  • The company is in pre-clinical development stage with no clinical data available yet.
  • Raphael Pharmaceutical Inc. has no revenue from product sales as it is in early development phase.

Opportunities

  • Raphael Pharmaceutical Inc. could benefit from increased demand for rheumatoid arthritis treatments in the US market.
  • The company may explore partnerships for clinical trials in the Health Care sector.
  • Raphael Pharmaceutical Inc. has potential to expand its product pipeline beyond rheumatoid arthritis and Covid-19.

Threats

  • Raphael Pharmaceutical Inc. faces competition from established pharmaceutical companies in the Health Care sector.
  • The company's reliance on CBD oil API may face regulatory challenges in the US market.
  • Raphael Pharmaceutical Inc. is vulnerable to delays in clinical trials for its product candidates.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.